V
Viia Valge-Archer
Researcher at AstraZeneca
Publications - 43
Citations - 3618
Viia Valge-Archer is an academic researcher from AstraZeneca. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 18, co-authored 38 publications receiving 2968 citations. Previous affiliations of Viia Valge-Archer include MedImmune.
Papers
More filters
Journal ArticleDOI
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Pauline Maby,Mihaela Angelova,David Tougeron,Sarah E. Church,Sarah E. Church,Sarah E. Church,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Maria Fischer,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Maristella Sasso,Maristella Sasso,Maristella Sasso,Amélie M. Bilocq,Amélie M. Bilocq,Amélie M. Bilocq,Amos Kirilovsky,Amos Kirilovsky,Amos Kirilovsky,Anna C. Obenauf,Mohamad Hamieh,Anne Berger,Patrick Bruneval,Jean-Jacques Tuech,Jean-Christophe Sabourin,Florence Le Pessot,Jacques Mauillon,Arash Rafii,Pierre Laurent-Puig,Pierre Laurent-Puig,Michael R. Speicher,Zlatko Trajanoski,Pierre Michel,Richard Sesboüé,Thierry Frebourg,Thierry Frebourg,Franck Pagès,Viia Valge-Archer,Viia Valge-Archer,Jean-Baptiste Latouche,Jérôme Galon,Jérôme Galon,Jérôme Galon +52 more
TL;DR: Assessment of the immune status via Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability staging that could be an important guide for immunotherapy strategies.
Patent
Antibodies against PD-1
Mary Collins,Clive Wood,Beatriz M. Carreno,Deborah Luxenberg,Jason Jussif,Laura L. Carter,Frances Bennett,Viia Valge-Archer,John Andrews,Caroline Russell +9 more
TL;DR: In this article, the authors provided antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular.
Journal ArticleDOI
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Amos Kirilovsky,Amos Kirilovsky,Amos Kirilovsky,Helen K. Angell,Anna C. Obenauf,Marie Tosolini,Marie Tosolini,Marie Tosolini,Sarah E. Church,Sarah E. Church,Sarah E. Church,Pauline Maby,Pauline Maby,Pauline Maby,Angela Vasaturo,Angela Vasaturo,Angela Vasaturo,Mihaela Angelova,Mihaela Angelova,Mihaela Angelova,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Stéphanie Mauger,Stéphanie Mauger,Stéphanie Mauger,Maximilian J. Waldner,Anne Berger,Michael R. Speicher,Franck Pagès,Viia Valge-Archer,Jérôme Galon,Jérôme Galon,Jérôme Galon +39 more
TL;DR: The data demonstrate the protective impact of the Immunoscore, a cytotoxic immune signature, and increased marginal lymphatic vessels, against the generation of distant metastases, regardless of genomic instability.
Journal ArticleDOI
Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
Frann Bennett,Deborah Luxenberg,Vincent Ling,I-Ming Wang,Kim Marquette,David C. Lowe,Nighat Khan,Geertruida M. Veldman,Kenneth Jacobs,Viia Valge-Archer,Mary Collins,Beatriz M. Carreno +11 more
TL;DR: It is suggested that IL-7 and IL-15 restore proliferation under conditions of PD-1 engagement by enhancing high-affinity IL-2R expression and hence,IL-2 responsiveness, and thus, STAT5 has been implicated in the maintenance of IL- 2Rα expression.
Journal ArticleDOI
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Suzanne Mosely,John E. Prime,Richard C.A. Sainson,Jens-Oliver Koopmann,Dennis Wang,Danielle Greenawalt,Miika Ahdesmaki,Rebecca Leyland,Stefanie R. Mullins,Luciano Pacelli,Danielle Marcus,Judith Anderton,Amanda Watkins,Jane Coates Ulrichsen,Philip Brohawn,Brandon W. Higgs,Matthew McCourt,Hazel Jones,James Harper,Michelle Morrow,Viia Valge-Archer,Ross Stewart,Simon J. Dovedi,Robert W. Wilkinson +23 more
TL;DR: Characterization of murine syngeneic tumor models highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo.